Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome

Status Terminated

Clinical Trial Summary

This is a prospective randomized double blinded study comparing the effect on duration of pharmacologic treatment and duration of hospital stay when using clonidine at 12 µg/kilogram/day as an adjunct to oral morphine as compared to morphine monotherapy in the management of term and near term infants with neonatal abstinence syndrome (NAS)

Clinical Trial Description

Neonatal abstinence syndrome (NAS) is an emerging epidemic and has lead to a tremendous increase in cost of medical care. Opioids are the mainstay of treatment for NAS although there are concerns about possible short-term and long-term effects including but not limited to adverse neurodevelopmental outcomes. Other drugs such as clonidine, phenobarbitone, methadone and buprenorphine have been evaluated to limit the postnatal exposure to opioids in these infants. Clonidine is an alpha 2 receptor and can lessen withdrawal manifestations. The addition of clonidine at 6 µg/kilogram/day to morphine in the management of NAS has been shown to reduce the duration of pharmacotherapy by about 27% in a previous study. A recent pilot study reported reduction of treatment duration for NAS with clonidine (12 µg/kilogram/day) monotherapy as compared to morphine monotherapy. The study reported no adverse effects in study subjects at the doses used in the study. The investigators hypothesize that there will be a minimum of 30% reduction in the treatment duration with 12 µg/kilogram/day clonidine used as adjuncts to standard morphine treatment as compared to morphine monotherapy in the management of term and near term infants with NAS ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03762317
Study type	Interventional
Source	Hennepin County Medical Center, Minneapolis
Contact
Status	Terminated
Phase	Phase 4
Start date	April 30, 2018
Completion date	December 12, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01965704` - Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women	Phase 2
Completed	`NCT03890562` - Assessing the Effects of Auricular Acupressure on Newborns With NAS	N/A
Completed	`NCT01958476` - Improving Outcomes in Neonatal Abstinence Syndrome	Phase 3
Active, not recruiting	`NCT01734551` - NAS Treatment - Opiate Versus Non-Opiate	Phase 4
Completed	`NCT00496951` - Vagal Tone and Neonatal Abstinence Syndrome	N/A
Completed	`NCT02851303` - Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome	Phase 4
Recruiting	`NCT05226624` - The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program	N/A
Completed	`NCT03670160` - Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome	Phase 2
Not yet recruiting	`NCT04611659` - Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine	N/A
Completed	`NCT01452789` - Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome	Phase 3
Completed	`NCT04588519` - tAN to Mitigate Withdrawal Behaviors in Neonates	N/A
Completed	`NCT02797990` - Conflict Between Maternal Autonomy and Child Health in Substance-use	N/A
Completed	`NCT02801331` - Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome	N/A
Terminated	`NCT03246243` - Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
Completed	`NCT03567603` - Sound Processing Changes in Babies With Opioid Exposure
Recruiting	`NCT06303986` - Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
Active, not recruiting	`NCT03725332` - The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky	N/A
Recruiting	`NCT04983563` - Actigraphy and Neonatal Abstinence Syndrome of Hospitalized Newborn in Intensive Care Units	N/A
Completed	`NCT04298853` - Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome	Phase 4
Completed	`NCT02182973` - Donor Human Milk in Neonatal Abstinence Syndrome